Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

Hospital de Cruces2 enrolled

Overview

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

The principal aim of this trial is to assess the safety of non-mutated HLA-identical Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of treatment with biphosphonates. Since MSC are inherently non-immunogenic and do not elicit proliferation of allogeneic lymphocytes (in co-culture experiments), a cell therapy based on HLA-identical or histocompatible (at least 5 shared out of 6 HLA antigens) allogenic MSC may be accomplished without subjecting the patients to immunosuppressor treatment. Adverse secondary effects due to immunosuppressor treatment will be avoided using this strategy thus patients may benefit from two cellular infusions. The patients will be followed for 2 years post their fifth and last MSC infusion.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Osteogenesis Imperfecta

Interventions

Mesenchymal Stem CellsBIOLOGICAL

Mesenchymal Stem Cell Infusions

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient age: older than 6 months and younger than 12 years old. * Patients with molecular confirmation of mutation in either COL1A1 or COL1A2 genes associated with OI (type III). * Patients with HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs. * All patients that fulfil the inclusion criteria regardless of whether or not they are undergoing biphosphonate treatment. * Patients whose parents or the legal guardians are willing to sign the consent forms to participate in this clinical trial. Exclusion Criteria: * Patient age: older than 12 years old * Patients lacking confirmation of mutation in either COL1A1 or COL1A2 genes associated with severe deforming OI (type III). * Other pathological subtypes of OI. * Patients lacking of HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs. * Immunodeficiencies and any other malignancies. * Participation in other clinical trial. * Any medical or psychiatric condition that in the researcher´s opinion could affect the patient´s ability to complete the trial or hamper the participation in the trial. * Patients whose parents or the legal guardians do not sign the consent forms

Locations (2)

Hospital Universitario Cruces

Barakaldo, Bizkaia, Spain

Hospital Universitario Getafe

Getafe, Madrid, Spain